Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preoperative Chemotherapy vs Chemotherapy Followed by Chemoradiotherapy in Rectal Cancer
NCT03875781Phase 3Recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jun 2019
- Primary completion
- Dec 2026
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of FOLFIRINOX in rectal cancer (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Progression-Free Survival at 3 years. Started Jun 2019; status: recruiting.
02
Drugs
FOLFIRINOX
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT03875781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03875781.